NeuroSense Therapeutics Ltd. (NRSNW) Capital expenditures 2021–2025
NeuroSense Therapeutics Ltd. (NRSNW) annual capital expenditure history — cash spent on property, plant and equipment, per SEC filings.
$8,000FY2025 · since FY2021: $17,000 → $8,000
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $8,000 | +166.7% |
| FY2024 | $3,000 | -89.7% |
| FY2023 | $29,000 | -58.6% |
| FY2022 | $70,000 | +311.8% |
| FY2021 | $17,000 | — |
Capital expenditures are shown as the positive cash amount spent, as reported on the cash-flow statement.
Source: SEC XBRL filings · For reference only · Not investment advice
More NRSNW financial trends
NRSNW RevenueNRSNW Net incomeNRSNW Net marginNRSNW Gross profitNRSNW Gross marginNRSNW Operating incomeNRSNW Operating marginNRSNW Operating cash flowNRSNW Free cash flowNRSNW Return on equityNRSNW Stock buybacksNRSNW Dividends paidNRSNW Total assetsNRSNW Total liabilitiesNRSNW Shareholders’ equityNRSNW overview →